Telomir Pharmaceuticals (NASDAQ:TELO) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Telomir Pharmaceuticals (NASDAQ:TELO) posted its quarterly earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01, FiscalAI reports.

Telomir Pharmaceuticals Trading Up 0.7%

Telomir Pharmaceuticals stock traded up $0.01 during mid-day trading on Tuesday, hitting $1.35. The company had a trading volume of 35,742 shares, compared to its average volume of 126,783. The company has a market capitalization of $46.41 million, a price-to-earnings ratio of -3.65 and a beta of -0.66. Telomir Pharmaceuticals has a 12-month low of $1.05 and a 12-month high of $4.81. The company’s fifty day moving average is $1.27 and its 200-day moving average is $1.36.

Hedge Funds Weigh In On Telomir Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Qube Research & Technologies Ltd acquired a new position in shares of Telomir Pharmaceuticals during the 2nd quarter worth about $33,000. XTX Topco Ltd purchased a new stake in Telomir Pharmaceuticals during the 4th quarter worth approximately $53,000. Bank of America Corp DE increased its stake in Telomir Pharmaceuticals by 283.9% during the 4th quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock worth $61,000 after buying an additional 10,880 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Telomir Pharmaceuticals during the second quarter valued at approximately $62,000. Finally, Marshall Wace LLP acquired a new position in shares of Telomir Pharmaceuticals during the second quarter valued at approximately $95,000.

Analysts Set New Price Targets

TELO has been the topic of a number of research reports. Rodman & Renshaw initiated coverage on shares of Telomir Pharmaceuticals in a research note on Tuesday, January 13th. They issued a “buy” rating on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised shares of Telomir Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold”.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.